|
|
|
|
Ruggero Della Bitta,
Senior Vice President Oncology Merck Serono Dr Ruggero Della Bitta is Board Certified in Internal Medicine & Hematology and has been trained in Medical Oncology at the University Politecnica delle Marche - Italy, where he currently is Ass. Professor in Internal Medicine, Hematology & Clinical Immunology.
In Merck Serono since 2004, he has been working in advancing the oncology pipeline forward as Head of Global New Therapies and is currently Head of Global Medical Affairs – Oncology BU.
He previously worked at Chiron/Novartis in the US & Europe and Quintiles Europe for 6 and 7 years respectively.
In these companies, he held various management positions within oncology R&D/MA in US and Europe and as Managing Director in Italy, contributing to the development and FDA/CHPM registration of oncology drugs (e,g, rh-IL2 Proleukin) and their commercial uptake.Appearing: DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 2.40pm A new paradigm: cancer-specific polyclonal antibodies to target cancer at the phenotypic level
- Limits of intracellular pathways inhibition and ‘superiority’ of phenotype vs genotype
- Considering the evolutionary shift from monotonal monotony to polyclonal immunologic diversity
- Solutions for developing polyclonal therapeutic strategies within the personalised cancer care
Ruggero Della Bitta, Senior Vice President Oncology,
Merck Serono 4.40pm Expert Q&A panel discussion: are we aiming at a moving target?
- Different approaches to targeted therapy: is the target actually the driving force?
- What are the implications for therapies which have an effect in patients without a particular target? Does this interrupt that targeted cancer therapy paradigm?
- Understanding strategies and solutions to improve targets for cancer therapy.
Ruggero Della Bitta, Senior Vice President Oncology,
Merck Serono Head of Experimental Oncology Department,
Institute de Recherche Pierre Fabre Chief Technology Officer,
Silicon Biosystems Senior Group Leader,
Friedrich Miescher Institute for Biomedical Research (Part of the Novartis Research Foundation) |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
